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BK Virus Nephropathy: Prevalence, Impact and 
Management Strategies
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Abstract: BK virus reactivation as a result of therapeutic immunosuppression following 
renal transplant can result in BK polyomavirus nephropathy and renal allograft loss. This is 
a complex and challenging clinical problem with a range of management options and 
practices reported in literature. The current standard for early diagnosis and treatment is 
surveillance by measuring viral DNA in blood using qPCR. Immunosuppression reduction is 
the cornerstone of effective management but is associated with a risk of acute rejection 
following treatment. 
Keywords: BK polyomavirus nephropathy, kidney transplant, immune monitoring, 
treatment, surveillance
Prevalence
BK polyoma virus (BKV) is a non-enveloped DNA virus first discovered in the 
urine of a kidney transplant recipient in 1971.1 Its genome has an early region 
which codes for the large and small T antigens, a late region which codes for the 
capsid proteins VP1-3, and agnoprotein, and a non-coding control region (NCCR). 
BKV strains have six genotypes based on polymorphisms in VP1 and NCCR.2
BKV is widely prevalent in general population with over 80% individuals 
having antibodies against BK virus.3,4 The most common mode of transmission is 
through respiratory secretions, resulting in a mild self-limited respiratory infection.5 
Viral spread to other organs is believed to be via bloodstream and in immunocom-
petent individuals, it remains clinically silent in renal tubular epithelium.
“Presumptive” BK Polyoma virus nephropathy (PVN) is defined as persistently 
high BK viral load in plasma >10,000 copies/mL for four weeks. Renal allograft 
biopsy remains the gold standard for diagnosing “definite” PVN.6–12 Since the 
allograft involvement is focal, and the possibility of sampling error is high, two 
cores containing medulla are required for an adequate biopsy sample.8,9 Intragraft 
polyomavirus gene expression on renal biopsy has recently been reported as 
a useful adjunct to the diagnosis of PVN with the potential to differentiate from 
T-cell-mediated rejection.13 Biopsy proven “definite” PVN has an incidence of 
5–6%, with a higher incidence in ABO-incompatible donors and following desen-
sitization in highly sensitized recipients.14–16
The Banff Working Group on Polyomavirus Nephropathy recently published 
a morphologic classification of definite PVN into three groups, Class I, II, and III, 
based on polyomavirus load and Banff ci score (interstitial fibrosis) for ease of 
diagnostic communication and comparative data analysis.17 However, this was 
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a retrospective observational analysis which has not been 
validated in a mixed population.
Impact
BK-virus-related disease is commonly seen in kidney trans-
plant and hematopoietic stem cell transplant recipients. The 
cause for reactivation is therapeutic immunosuppression (IS) 
following transplant.18 BK viruria can be seen in 60% of 
kidney transplant recipients, while BK viremia is seen in up 
to 13% kidney transplant recipients, and nephropathy in 
10%.19–21 The actual reported incidence varies; however, 
with the choice of induction IS, maintenance IS, and screen-
ing modality used, hence the wide variations in literature. In 
US, 5.7%– 7.5% of renal allografts are lost to PVN.22
PVN is therefore a serious clinical problem in kidney 
transplantation. PVN is difficult to treat since there is no 
BKV-specific anti-viral therapy. Any anti-virals currently in 
use work poorly and suffer from substantial host toxicity. 
PVN is treated by stimulating host immune response by IS 
reduction; however, there is a risk of acute rejection follow-
ing virus clearance,23 further complicating treatment options 
since rejection treatment requires escalation of IS which 
often results in BKV recurrence.
The current standard for management is monitoring for 
viral DNA using qPCR. Other investigational surveillance 
tools include monitoring BKV-specific CMIR,24 and 
donor-derived cell-free DNA (dd-cfDNA). dd-cfDNA is 
a non-specific marker of injury. Since BKV causes inter-
stitial inflammation and tubulitis, elevated levels of dd- 
cfDNA have been reported in a study of allograft rejection 
in kidney transplant in the setting of PVN.25 Since BKV is 
also known to be associated with development of de novo 
donor-specific antibodies (DSA),26 elevated dd-cfDNA 
levels in this infection could actually represent alloanti-
body-mediated microcirculation injury. Persistent viremia 
(lasting >140 days) was found to be strongly associated 
with development of Class II DSAs. The association of 
Class II DSA with antibody-mediated rejection (ABMR) 
and graft loss is well known.27
Most studies have found that humoral immune response 
does not play a significant role in preventing development 
of PVN.28 Despite the presence of a high level of antibo-
dies, patients with PVN can have high levels of viral load 
and low CD8+ T cells.29 BKV-specific cell-mediated 
immune response (CMIR) was demonstrated in normal 
individuals to be the mechanism responsible for prevention 
of BKV reactivation in immunocompetent individuals.30 
Low levels of BKV-specific interferon-gamma (IFNγ) pro-
ducing T cells correlate with progression to PVN, while 
reconstitution of these cells correlates with resolution of 
nephropathy.31–34 Immune monitoring could help in identi-
fying patients at risk of PVN;34–38 however, this knowledge 
is still evolving and has not been used in guiding treatment 
recommendations.
Figure 1 Monitoring and treatment protocol for BK viremia at our center.
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Management Strategies
Risk Factors
The most common factor associated with risk of developing 
PVN is the intensity of immunosuppression. Donor factors 
associated with a higher risk include transplanting kidney 
from BKV seropositive donor to seronegative donor,39,40 
number of HLA mismatches, ABO-incompatibility, and 
ischemia reperfusion injury.6,14,41,42 Recipient factors include 
old age, male sex, desensitization, and prior kidney transplant 
with PVN.16,43
Surveillance
The mainstay of treatment of PVN is immunosuppression 
reduction. A wide variation in treatment practices is 
observed based on individual clinician experience. Most 
centers monitor BKV post-transplant at 3, 6, 9, and 12 
months.44 However, with more intense induction regimen 
or in those with risk factors, it is prudent to perform 
routine surveillance at monthly intervals in the first 12 
months following transplant. This is standard in our center. 
In addition to following viral loads with qPCR, we also 
follow ImmuKnow Immune Cell Function Assay (Cylex 
Inc., Columbia, MD, USA) as an indirect measure of 
CMIR. Our approach is outlined in Figure 1.
Immunosuppression Reduction and 
Antiviral Therapy
For BKV viral load <10,000 copies/mL, IS dose reduction 
should be considered. For viral loads >10,000 copies/mL, 
a common initial approach involves calcineurin inhibitor 
dose reduction by 25–50%. Switching to Cyclosporine 
A (CsA) has been shown to have some benefit as well.45 
Switching from Tacrolimus to CsA is a common approach 
used in our center in patients with persistent viremia; 
However, a higher incidence of biopsy-proven acute rejection 
is seen with this approach.46 Failure of reduction in viral load 
should prompt reduction of mycophenolate mofetil (MMF) by 
50%, or discontinuation of MMF or switching to an mTOR 
inhibitor.47,48 Switching from MMF to Leflunomide is another 
option associated with favorable outcomes.49–52 We routinely 
switch from MMF to Leflunomide in our center; however, the 
practices vary by center and physician experience. In refrac-
tory cases, most common therapeutic option is Cidofovir, use 
of which is limited by its nephrotoxicity.53–55 Brincidofovir is 
a prodrug of cidofovir and has also been used with limited 
success.56,57 IVIG preparations have high titers of neutralizing 
antibodies to BK virus and can help expedite virus clearance 
and have been used as a useful adjunctive therapy.58–61 
Fluoroquinolones have been tried but failed to show 
Table 1 Anti-Virals for PVN
Anti-Virals
Name Class/Mechanism Dose Comments
Leflunomide49–52 Anti-Inflammatory; Anti-Viral; 
Immunosuppressive
PO: Loading- 100 mg daily for 3–5 
days; maintenance- 20-60 mg qD; 
Trough Level −50-100 μg/mL
Can be used following 
discontinuation of MMF.
Cidofovir53–55 Nucleoside analog IV: 0.25–1.0 mg/Kg at 1–3 weeks Used in refractory cases; 
Nephrotoxicity is the most 
serious adverse effect.
Brincidofovir56,57 Investigational Prodrug of Cidofovir; Anti-viral 
activity





Immunoglobulin preparation with high titers of 
neutralizing antibodies to BK virus
IV: 0.25–2.0 g/Kg Can be used as an adjunct to 
other measures in refractory 
cases.
Levofloxacin62–64 Fluoroquinolones; Antiviral, inhibit helicase 
activity of large T antigen
PO: 500 mg qD (renally adjusted) Levofloxacin failed to show 
benefit in randomized controlled 
trials.
Everolimus47,48 Inhibits mammalian target of rapamycin (mTOR) 
kinase activity, inhibiting T and B lymphocyte 
activation and proliferation.
PO 0.75 mg twice daily adjusted to 
trough levels of 3–8 ng/mL.
Can be used following 
discontinuation of MMF. Limited 
literature supporting its use.
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therapeutic benefit.62–64 There is no strong evidence support-
ing antiviral treatment for PVN;46 however, for patients with 
persistent BK viremia despite adequate immunosuppression 
reduction, therapeutic options are outlined in Table 1.
Conclusion
Due to lack of strong evidence, no strong treatment recom-
mendations can be made; however, it is prudent to start 
with immunosuppression reduction and add anti-virals for 
persistent viremia not responding to immunosuppression 
reduction based on physician experience. Regular monitor-
ing of qPCR remains the cornerstone of early diagnosis 
and treatment. Novel monitoring strategies being investi-
gated include immune monitoring and ddcf DNA.
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